Surveillance of safety of medicinal products in their medical use – one of the pillars of LUMIER PHARMA LLC corporate policy

Surveillance of the safety of medicinal products in their medical use in Ukraine is regulated by Order of MoH Ukraine of 27.12.2006 no. 898 “On Approval of Procedure for Surveillance” registered in the Ministry of Justice of Ukraine on December 19, 2016 under No. 1649/29779 (as amended by the Order of the Ministry of Health of Ukraine dated 09.26.2016, No.996)

LUMIER PHARMA LLC as a manufacturer of prescribed vital medicinal products to treat cancer, tuberculosis, blood diseases, chronic viral hepatitis is responsible for its products and cares about the health of patients. To ensure monitoring of the safety and effectiveness of medicinal products the company has created the pharmacovigilance system. It promotes increase of responsibility for the quality and safety of medicines, as well as allows taking appropriate measures aimed at improving the safety of medicinal products.

In case of any adverse side effects or lack of efficacy as a result of administration of medicinal products produced by the company “LUMIER PHARMA” LLC, please report them to QPPV in any of the following ways:

1. By phone: +38 (044) 229-43-89, mob. +38 (050) 630-27-10

2. By e-mail: vigilance@lumier-pharma.com or l.nikitchenkova@lumier-pharma.com, completing The report on the adverse reaction;

Download the report on adverse reactions or lack of efficacy of the product in the format MS Word (.doc)